Danaher completed the acquisition of Abcam for $5.7bn.

Danaher, a global science and technology innovator, completed the acquisition of Abcam, a global supplier of protein consumables, for $5.7bn. "We couldn't be more excited to have Abcam join Danaher. Abcam's long track record of innovation, outstanding product quality and breadth of antibody portfolio positions them as a key partner for the scientific community. We look forward to welcoming Abcam's innovative and talented team to Danaher as we continue to help our customers solve some of the world's biggest healthcare challenges," Rainer M. Blair, Danaher President and CEO.